Kuehne + Nagel and GlaxoSmithKline sign long term global logistics partnership contract



Kuehne + Nagel and GSK signed an end-to-end global logistics partnership until 2021 that will see Kuehne + Nagel run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company, Kuehne Nagel informed.
The contract officially marks the commencement of a relationship which brings significant logistics alignment between the two companies; with Kuehne + Nagel providing skills, expertise and strategic capability to deliver enhanced value across GSK’s global supply chain operations., it was stated in the announcement.
- With numerous suppliers, a large number of manufacturing units and a variety of specific routes to patients and consumers in over one hundred countries; GSK requires a sophisticated and truly global end-to-end logistics solution. Kuehne + Nagel was selected as a partner due to the company’s existing track record with GSK, strength in the industry, maturity of Integrated Logistics provision and significant investment strategy in pharmaceuticals and consumer products logistics- it was stated in the announcement.
Detlef Trefzger, Chief Executive Officer of Kuehne + Nagel International AG, stated that they are very excited about this long term collaboration with GSK.
-Our focus is to leverage existing experience and industry-specific solutions serving the pharmaceutical and consumer sector which will deliver incremental benefits to GSK. Our integrated logistics approach, comprising air, sea, overland services and Logistics Control Centres in four regional hubs will enable GSK’s global supply chains to move to the next level of performance
As announced, the new working relationship is a transformation development for GSK and Kuehne + Nagel in its scale and ambition.
- It is one of Kuehne + Nagel’s biggest customer awards and marks significant progress towards realizing both GSK’s ambition of a world class supply chain and Kuehne + Nagel’s goal to be the leading provider of end-to-end solutions in the pharmaceutical and consumer sectors.